Our commercially available tests provide information that can help advanced cancer patients obtain the right treatment and pharmaceutical companies bring new therapies to market faster.

All our solutions for patients with cancer are supported by Guardant’s proprietary Digital Sequencing technology. We combined robust, high-efficiency biochemistry at the front-end, with next-generation sequencing and a machine-learning augmented bioinformatics pipeline, to create a platform we believe delivers the clinical sensitivity levels necessary for best-in-class products today and tomorrow across all stages of cancer.

Treatment selection for patients
with advanced cancer

Certain cancer therapies provide better patient outcomes and fewer side effects than broad-based chemotherapy. But an individual’s response to a given treatment often depends on the tumor’s genomic profile.

For oncologists, Guardant360 provides comprehensive genomic results from a simple blood draw in approximately seven days, helping them move beyond the limitations of tissue biopsies to match patients with the best treatments. Obtaining clinically relevant genomic information through a blood draw helps them avoid an additional tissue or surgical biopsy and moves beyond the limitations of tissue specimens. Guardant360 covers all genes recommended for profiling by the National Comprehensive Cancer Network, including the 73 genes most relevant to clinical care.

Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists and all 27 National Comprehensive Cancer Network Centers.

If you are a healthcare provider looking for information about Guardant360, please visit our product website.


Clinical Samples Reported


Biopharma Partners


Ordering Oncologists


Clinical Outcomes Studies Published

Accelerating Clinical Trials

For pharmaceutical companies, Guardant360 offers a way to accelerate clinical development programs through retrospective sample analysis, patient screening and clinical trial enrollment, and companion diagnostic development to support commercialization of new drugs.

Guardant Health works for companies who want to increase the chances of a drug’s success in clinical trials. Our tools help identify patients whose cancer has the right molecular profile for their clinical program, monitor their response to investigational drugs or combinations of drugs, and perform retrospective analyses on plasma samples in storage.

Industrywide, nearly 70 percent of the oncology drug development pipeline in 2016 was for targeted therapies and immunotherapy agents.

GuardantOMNI, launched in 2017, is designed for biopharmaceutical customers to use as a comprehensive genomic profiling tool to help accelerate clinical development programs in immuno-oncology and targeted therapy. A 500-gene panel with breadth that is significantly larger than that of Guardant360, with comparable performance incorporating the vast majority of all genes being evaluated in cancer drug development pipelines and biomarkers for immuno-oncology applications, including tumor mutational burden.

Companies who want to increase the chances of a drug’s success in clinical trials use GuardantOMNI to help identify patients whose cancer has the right molecular profile for their clinical program. GuardantOMNI also helps monitor patient response to investigational drugs or combinations of drugs, and perform retrospective analyses on plasma samples in storage.

Recurrence Detection
and Residual Disease Detection

Guardant leverages the data from the tens of thousands of samples sequenced to date to help better understand cancer and shape future products. The deep biological insights obtained to date have already laid the groundwork for future breakthroughs by enabling potentially improved sensitivity and specificity for recurrence monitoring and early detection.

For patients who have had an early-stage tumor removed, follow-up testing is often done on an ad-hoc basis. Knowing whether the surgery was successful could provide peace of mind or present the opportunity for additional treatment with an intent to cure.

Our LUNAR-1 program seeks to provide a definitive test for recurrence, moving beyond the limitations of today’s methods. We intend to introduce a new blood test in 2018 that biopharma companies can use to identify new drug development opportunities to serve these patients. This program’s initial focus will be on lung, breast, colorectal, and ovarian cancers.

Early detection

Regular cancer screening is a proven way to find cancer early, when it can be most-easily cured. Yet many people are not screened — and those who are don’t always get accurate results due to limitations of today’s screening technologies.

To help high-risk populations identify cancer at the earliest stages, we are developing a blood-based test that seeks to overcome the technical and clinical challenges of existing screening methods. In partnership with the biopharma industry, we believe our work could spur the development of new preventative measures and early treatments that could extend the lives of cancer patients and one day reduce new cancer diagnoses.

Our LUNAR-2 research and development program is working towards developing an accurate, affordable blood test for widespread use among higher-risk asymptomatic individuals. We are leveraging data from tens of thousands of advanced cancer samples today and will leverage data from thousands of early stage cancer samples in the future to potentially develop tests with unprecedented sensitivity and specificity for the detection of cancer as early as possible. We are collaborating with multiple investigators at a cancer centers around the world in pursuit of this goal.